Original from: Devyser
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser¡¯s unique assays in its CLIA-certified laboratory.
The companies will work together to promote the Devyser laboratory services to support and advance research and development for pharmaceutical companies.
¡°We are very excited to enter into this agreement. Being able to support pharmaceutical companies¡¯ development projects to enable new and improved therapies is a part of our vision for Devyser. We are convinced that Thermo Fisher, with its global network and outstanding reach, will provide a strong platform for partnering with global pharmaceutical companies in addition to Devyser¡¯s own discussions,¡± says Fredrik Alpsten, CEO at Devyser.¡° This collaboration is in line with our strategy to expand our presence in the US.
Devyser established the US CLIA-certified laboratory during the spring of 2023 and received CLIA certification from the Centers for Medicare and Medicaid Services (CMS) in May 2023. The laboratory is based in Atlanta, Georgia.
Devyser and Thermo Fisher entered an exclusive collaboration and distribution agreement in April 2023 providing Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser¡¯s post-transplant diagnostics portfolio of NGS products in North America and Europe. Recently, Devyser announced an expansion of the commercial collaboration with Thermo Fisher by including Brazil as a territory.
